Here is a list of research studies about MOTS-c peptide:
Preclinical studies:
- MOTS-c improves insulin sensitivity and glucose metabolism in obese mice. Lee C, et al. Cell Metab.
- MOTS-c prevents pancreatic islet destruction in autoimmune diabetes in mice. Kong BS, et al. Cell Rep.
- MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis in mice. Reynolds JC, et al. Nat Commun.
- MOTS-c translocates to the nucleus to regulate nuclear gene expression in response to metabolic stress in mice. Kim KH, et al. Cell Metab.
- MOTS-c protects against neurodegeneration in animal models of Alzheimer’s disease and Parkinson’s disease. Lee H, et al. Int J Mol Sci.
- MOTS-c protects against cardiovascular disease in animal models of heart disease and stroke. Zhao Y, et al. Front Pharmacol.
Clinical trials:
- A clinical trial to investigate the safety and efficacy of MOTS-c peptide for the treatment of obesity is currently underway.
- A clinical trial to investigate the safety and efficacy of MOTS-c peptide for the treatment of type 2 diabetes is currently underway.
These are just a few examples of the many research studies that have been conducted on MOTS-c peptide. The results of these studies suggest that MOTS-c peptide has the potential to be used to treat a variety of conditions, including obesity, type 2 diabetes, muscle wasting, osteoporosis, and neurodegenerative diseases.
However, more research is needed to fully understand the safety and efficacy of MOTS-c peptide in humans. The clinical trials that are currently underway are expected to provide more information about the potential benefits and risks of MOTS-c peptide for the treatment of obesity and type 2 diabetes.
If you are interested in learning more about MOTS-c peptide or participating in a clinical trial, talk to your doctor.
